Exploring European Undervalued Small Caps With Insider Action In June 2025
Name
PE
PS
Discount to Fair Value
Value Rating
Stelrad Group
12.0x
0.7x
39.10%
★★★★★★
Morgan Advanced Materials
11.9x
0.5x
33.98%
★★★★★☆
Tristel
29.0x
4.1x
9.93%
★★★★☆☆
A.G. BARR
19.2x
1.8x
44.22%
★★★★☆☆
Nyab
21.6x
0.9x
33.43%
★★★★☆☆
NOTE
20.0x
1.3x
-39.56%
★★★☆☆☆
Absolent Air Care Group
22.1x
1.7x
49.73%
★★★☆☆☆
Fuller Smith & Turner
12.0x
0.9x
-33.13%
★★★☆☆☆
Eastnine
18.8x
9.1x
37.36%
★★★☆☆☆
Seeing Machines
NA
2.6x
39.56%
★★★☆☆☆
Click here to see the full list of 65 stocks from our Undervalued European Small Caps With Insider Buying screener.
We're going to check out a few of the best picks from our screener tool.
Simply Wall St Value Rating: ★★★★★☆
Overview: Coats Group is a global leader in industrial thread manufacturing, serving the apparel, footwear, and performance materials sectors with a market capitalization of approximately £1.5 billion.
Operations: The company's revenue is primarily derived from three segments: apparel, footwear, and performance materials. Over recent periods, the gross profit margin has shown an upward trend, reaching 36.28% as of June 2024. Operating expenses are a significant cost component, with general and administrative expenses consistently being a substantial part of these costs. The net income margin has also experienced growth in recent years, indicating improved profitability from operations despite fluctuating non-operating expenses.
PE: 21.1x
Coats Group, a European company with small cap characteristics, is making strategic moves to enhance its financial position. Recent insider confidence was demonstrated through share purchases in early 2025. The company plans to exit its US Yarns business, aiming for improved EBIT margins and a more focused portfolio. Despite relying on external borrowing, Coats maintains good cash flow coverage of debt and reported organic revenue growth of 4% from January to April 2025. Earnings are projected to grow over 21% annually.
Take a closer look at Coats Group's potential here in our valuation report.
Evaluate Coats Group's historical performance by accessing our past performance report.
Simply Wall St Value Rating: ★★★★★☆
Overview: Morgan Advanced Materials operates in the sectors of thermal products, performance carbon, and technical ceramics, with a market capitalization of £1.04 billion.
Operations: Morgan Advanced Materials generates revenue primarily from its Thermal Products (£419.90 million), Performance Carbon (£345.70 million), and Technical Ceramics (£337.80 million) segments. The company's gross profit margin has shown variability, with a recent figure of 11.39% as of June 2023, reflecting the relationship between revenue and cost of goods sold over time.
PE: 11.9x
Morgan Advanced Materials, a small-cap player in Europe, demonstrates insider confidence through recent share purchases. Despite relying solely on external borrowing for funding—considered higher risk—the company maintains a solid financial stance with high-quality earnings. The forecasted 18% annual earnings growth highlights potential for future expansion. Recent events like the Annual General Meeting in March 2025 reflect ongoing corporate activities and strategic planning, positioning Morgan Advanced Materials as an intriguing prospect within its industry context.
Navigate through the intricacies of Morgan Advanced Materials with our comprehensive valuation report here.
Assess Morgan Advanced Materials' past performance with our detailed historical performance reports.
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Xvivo Perfusion specializes in developing and commercializing medical technologies for organ transplantation, with a market cap of SEK 8.79 billion.
Operations: The company generates revenue primarily from its Thoracic, Abdominal, and Services segments, with Thoracic being the largest contributor at SEK 576.05 million. The gross profit margin has shown variability over time but was recorded at 74.95% as of December 31, 2024. Operating expenses are significant, driven by sales and marketing along with research and development costs.
PE: 65.4x
Xvivo Perfusion, a European small-cap company, showcases potential with projected earnings growth of 47.85% annually. Despite a net loss of SEK 12.4 million for Q1 2025, sales increased to SEK 218.59 million from the previous year's SEK 186.02 million, indicating revenue momentum amid financial challenges linked to reliance on external borrowing for funding. Insider confidence is evident as COO & Deputy CEO Lena Hagman recently purchased shares worth approximately SEK 466,500 in April, demonstrating faith in the company's future prospects despite current hurdles like board changes and audit re-elections at their AGM.
Dive into the specifics of Xvivo Perfusion here with our thorough valuation report.
Gain insights into Xvivo Perfusion's past trends and performance with our Past report.
Gain an insight into the universe of 65 Undervalued European Small Caps With Insider Buying by clicking here.
Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LSE:COA LSE:MGAM and OM:XVIVO.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Condé Nast Traveler
23 minutes ago
- Condé Nast Traveler
Inside the Leather Workshops of Andalusia
Menacho opened his workshop in the whitewashed village of Castilblanco de los Arroyos, a 45-minute drive north of Seville, a decade ago—but had never planned to work with leather. A keen equestrian, he wanted to become a riding instructor but failed the entrance exam. 'The following week they called me to see if I wanted to join the saddlery course instead,' he says. 'I said yes because I'd always enjoyed working with my hands. I learned cutting and stitching, how to differentiate between leather types, and how to make basic riding bags,' he says. It was through making saddles, tack, and other equestrian items, that he acquired the techniques that would make him a leading leathermaker in Spain—and across the fashion world. But the craft, and the ancient artisanal methods he follows, holds a deep significance for Menacho. Leatherwork in Andalusia dates back as far as the Islamic period, when cities like Córdoba became hubs for the trade. 'For me, it's a way of life and a symbol of identity,' he says. This history, and the region's deep connection with horses—as seen through its rich culture of agriculture and equestrianism—has led generations of Sevillian leather workers to hone and evolve the craft. Sacred art related to Seville's Semana Santa Easter festivities is at the root of many artisans' designs, while others are inspired by the city's rich mix of Moorish, Gothic, Mudejar, Renaissance and Baroque architecture. But artisanal work is hard work, and a number of craftspeople are beginning to rely more on machinery than the traditional methods to create their products. Younger generations, meanwhile, are moving away from the professions of their parents to embark on more modern careers. Both are developments that Menacho and many of his peers worry will not only dilute the quality of the product, but this intrinsic part of Andalusian life more deeply, too. 'The work of an artisan is culture, art, and history, but it can also be the future,' he says. 'I try to show people the real value of artisanal work so that we don't lose it.' Menacho, whose workshop is almost entirely free of machinery, does 90% of his work by hand Cristina Gómez Ruiz Techniques done by hand by artisans like Menacho distinguish, in their book, their work from industrial product Cristina Gómez Ruiz Menacho's own leather craft involves chiseling and scoring, die-cutting and stitching, embossing and gilding. He treats his leathers the traditional way with vegetable dyes in oak barrels, a process that can take between six and twelve months. His workshop is practically free of machinery, and 90% of the work he does is by hand, often using techniques that date back centuries, something that Menacho feels distinguishes an artisanal product from something industrial. 'The old, traditional methods are the ones that really work. Some of them date back 500 or 800 years. They're based on time, rhythm, and knowledge of materials,' he says.
Forbes
24 minutes ago
- Forbes
Truckin' To 2030: Europe's Green Horizon For Medical Cannabis & Hemp
Europe's cannabis sector is undergoing a profound transformation—one driven by evolving regulations, changing social attitudes, and rising institutional investor interest. Germany, as the continent's largest economy, stands at the heart of this transition, leading a dual trajectory in both medical cannabis and industrial hemp. What was once niche is now positioned as a cornerstone of sustainable health, clean materials, and innovative investment opportunities. You might say that the European industry appears to be built to last. Market Overview and Segmentation Europe's cannabis landscape is divided into two distinct segments: THC‑containing cannabis (above 0.3% THC), regulated primarily for medical and sometimes adult-use purposes; and industrial hemp (below 0.3% THC), employed in foods, textiles, bioplastics, cosmetics, and construction. While sharing a botanical origin—Cannabis sativa L.—each operates under its own regulatory framework, supply chain, and market focus. Understanding this segmentation is essential for investors and policymakers evaluating risk and opportunity. Globally, the medical cannabis market was valued at approximately €4.5 billion in 2024 and is projected to reach over €62 billion by 2030—recording a staggering compound annual growth rate (CAGR) of 55%. Europe, fueled by demographic shifts and legal liberalization, is forecasted to be the fastest-growing region. Meanwhile, the industrial hemp market is poised to triple to around €15 billion by 2030, according to UNCTAD projections, driven by surging demand for climate-friendly materials and plant-based nutrition. Regulatory Developments The eyes of the world are on Germany, as it has emerged as the regulatory focal point in Europe. Its Cannabis Act (CanG), enacted in 2024, removed restrictive quotas and significantly expanded medical access. A complementary Medical Cannabis Act (MedCanG) is under development, emphasizing pharmacy-based distribution while tightening telemedicine channels. In parallel, a new Industrial Hemp Liberalization Act is expected in 2026, poised to eliminate outdated restrictions and modernize hemp production regulation. On the EU level, the classification of CBD as a Novel Food is opening doors to wellness and nutrition markets previously inaccessible for hemp producers. Growth in Medical Cannabis Since medical cannabis legalization in 2017, German patient numbers have soared—with 300,000 individuals receiving prescriptions in 2024, estimated to grow to 840,000 in 2025. By 2030, the market is expected to reach €650 million. Innovations in formulation—such as high-purity extracts, dronabinol pills, and cannabinoid pastilles—are expanding therapeutic use across neurology, chronic pain, and oncology. Major operators like SYNBIOTIC SE are leading the charge, developing standardized dosage forms and investing in regulated production. Global companies such as Tilray, Aurora, OrganiGram, and Canada's Sanity Group (via its partnership with OrganiGram) are deepening their European presence, underlining the continent's rising magnetism for international cannabis investors. Industrial Hemp as a Sustainability Engine Industrial hemp, long undervalued, is now recognized as a strategic asset in Europe's green economy. German industrial hemp sales grew from €526 million in 2023 to a projected €3 billion by 2032 (CAGR ~22%). Applications range from hemp-protein powders to sustainable building insulation and biodegradable packaging. EU regulatory shifts—especially Novel Food approvals for CBD—further enable consumer-facing products. Companies such as Hempro International and new-era ventures targeting hemp-based construction materials and plant-based supplements illustrate the growing breadth of the market. Investment Opportunities and Strategic Challenges Europe is increasingly attractive to North American capital. SYNBIOTIC SE exemplifies a diversified strategy, combining medical cannabis and hemp under a unified corporate model. The publicly traded holding company expects revenues to climb from €26 million in 2025 to €47 million by 2027, with positive EBITDA forecasted in 2026. This dual exposure provides a hedge against regulatory divergence and price compression in either sector. David Hyde, founder and CEO of Hyde Advisory & Investments, plays a pivotal role in monitoring and facilitating cannabis investments in Germany. Through his firm's expert brokerage services, Hyde navigates complex regulatory frameworks, matches strategic partners, and helps investors identify high-quality medical cannabis assets in the German market. Drawing from his firm's insights, Hyde notes: Germany's medical cannabis market continues to grow, albeit more slowly than Australia's. While German market competition is increasing, there is lots of room for new brand/category entrants with proper market research, understanding of developed cannabis markets and the right distribution partner(s)." Several industry leaders are confident that Europe represents the next major frontier for cannabis investment. As Boris Jordan, Executive Chairman of Curaleaf, put it, '[Europe is the next big market for cannabis after the U.S.]' Meanwhile, Irwin Simon, CEO of Tilray, emphasizes the scale of the opportunity: 'Germany's de-scheduling of cannabis opens the path to new opportunities in a potential $3 billion medical market; the European Union medical cannabis market is now projected to become $45 billion.' Constantin von der Groeben, founder of Demecan, reflects on Germany's growth momentum: 'The market is on a constant growth that is overwhelming,' while Beau Whitney, head economist at Whitney Economics, sees a broader European transformation underway: 'We can expect an accelerated expansion in the EU of legalised cannabis… If countries reform quickly, then the EU could supplant the U.S. as the major leader in global cannabis reform.' Yet investors must navigate risks: regulatory uncertainty (especially around telemedicine and CBD policy), intense price competition as production scales, limited banking integration, and macroeconomic volatility. The fragmented legal landscape further complicates capital deployment in cannabis-related ventures. Why Legalization Is Working The legalization model in Europe—and particularly in Germany—has shown measurable success. Its framework promotes transparency, standards for safety and quality, and integration into conventional health systems. The emphasis on licensing, standardized extracts, and court-regulated pharmacies mirrors a methodical approach, providing market certainty for investors and patients alike. Moreover, reform frameworks that prioritize illicit-market conversion—such as transitioning traditional, unregulated growers into legal cooperatives—mirror best practices championed by analysts like Whitney Economics. This conversion aligns economic incentives, reduces social harms, and demonstrates the sustainability of the legal regime. Outlook to 2030 As of 2025, both medical cannabis and industrial hemp are poised to become multibillion-euro pillars of Europe's economy. By 2030, medical cannabis in Europe could exceed €10 billion, while industrial hemp ascends as an eco-driven mainstay. Companies rooted in innovation, regulatory compliance, and product diversification will lead market consolidation. Germany will remain the driving force behind this evolution—acting as the regulatory pioneer and investment hub for cannabis in Europe. Institutional and private investors seeking long-term value should consider pan-European platforms that bridge both cannabis segments, such as publicly traded SYNBIOTIC SE. Their IFRS-audited integrated model reflects the shift to a new chapter in medicine and an innovative sustainable economy. END NOTES: CanG Gesetz 2024 – UNCTAD 2022 – Cannabissciencetech 2024 – CannaMonitor 2025 – Credence Research – Grand View Research – IMARC Group – Luminorecruit 2025 – MJBizDaily 2024 – Novel Food – OrganiGram/Sanity Group 2024 – Research And Markets 2024 – Reuters 2024 – Statista – Weedman 2025 –
Yahoo
an hour ago
- Yahoo
Upstart (UPST) Slashes 7.7% on $500-Million Fundraising Program
We recently published . Upstart Holdings, Inc. (NASDAQ:UPST) is one of the best-performing stocks on Monday. Upstart Holdings dropped its share prices for a second day on Monday, shedding 7.71 percent to close at $63.46 apiece as investors soured on its plans to raise $500 million from the issuance of convertible senior notes. In a statement, Upstart Holdings, Inc. (NASDAQ:UPST) said that the notes will have a tenor of 7 years and will mature in 2032, unless earlier converted, repurchased, or redeemed. It also granted the initial buyers an option to purchase up to $75 million within a 13-day period beginning on the date the notes are first issued. The notes can be converted into cash or shares of its common stock, or they can prefer to convert into a combination of both. According to Upstart Holdings, Inc. (NASDAQ:UPST), proceeds from the offer will be used to pay the cost of the offering, as well as repurchase for cash a portion of its outstanding 0.25 percent Convertible Senior Notes due 2026. Photo by Clay Banks on Unsplash The balance will be allocated for general corporate purposes, which may include the repayment or retirement of existing debt, including the repurchase or retirement of the 2026 Notes. While we acknowledge the potential of UPST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
